Study: NCT02789657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 administered weekly with no planned treatment breaks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 administered weekly with no planned treatment breaks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 administered weekly with no planned treatment breaks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 2 administered weekly with no planned treatment breaks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: breast conserving or mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: breast conserving or mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: breast conserving or mastectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast surgery
Description: breast conserving or mastectomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC
Description: doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC
Description: doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles~Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles~Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles